Sponsored by the Multidisciplinary Association for Psychedelic studies (MAPS), this Phase II clinical pilot study explores the safety and efficacy of administering MDMA in conjunction with Psychotherapy to participants with treatment resistant Posttraumatic Stress Disorder (PTSD). Evidence in completed phase II trials, and preliminary findings in this phase II trial show promising results in reducing PTSD symptoms with a good safety profile.  Given the limited effectiveness of current available medications and therapeutic strategies, MDMA-assisted psychotherapy holds promise as a treatment option.  This talk will focus on methodology as well as individual participant experiences.
Biography
Marcela Ot’alora G. was born and raised in Colombia, S.A. and now lives in Boulder, Colorado, USA. She has a MA in Transpersonal Psychology and a MFA in Fine Arts. Marcela is dedicated to the treatment and research of trauma, first through art and later through the use of MDMA-assisted Psychotherapy. She worked as a co-therapist in the first government approved MDMA-assisted psychotherapy study in Madrid Spain and is the Principal Investigator of the Phase II MDMA-assisted psychotherapy study in Boulder, Colorado.

The first randomized, double-blinded, placebo-controlled Phase 2 study of MDMA-assisted therapy for the treatment of social anxiety in autistic adults is nearing completion. Fear and avoidance behaviors associated with social anxiety interfere with the ability to work, attend school, and develop relationships. The search for psychotherapeutic options for autistic adults who want to improve social adaptability is imperative considering the lack of effective conventional treatment options for this population in which social anxiety is common. This talk will feature an overview of the research as well as preliminary findings.
Biography
Alicia Danforth, PhD is a clinical psychologist and co-investigator for a current phase 2 randomized, double-blinded, placebo-controlled pilot study on the effects of MDMA-assisted therapy on social anxiety in autistic adults. Her dissertation research was on the subjective MDMA/ecstasy experiences of adults on the autism spectrum. She began her work in clinical research with psychedelic medicines with Charles Grob, MD at the Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center in 2004. She co-facilitated sessions for the first clinical trial of psilocybin treatment for existential anxiety related to advanced cancer since psilocybin became a controlled substance in the United States. She also co-developed and taught the first graduate-level course on psychedelic theory, research, and clinical considerations for therapists and researchers at the Institute of Transpersonal Psychology.

This presentation will summarize past and ongoing studies from the Johns Hopkins Psilocybin Research Project, which started about 15 years ago. Laboratory research includes administering psilocybin to healthy volunteers, psychologically distressed cancer patients, cigarette smokers seeking abstinence, ordained clergy, and beginning and long-term meditators. The results from several studies suggest that mystical-type experiences appear to mediate sustained positive changes in attitudes, moods, and behavior. Individuals responding to recruitment for a “bad trip” survey on the internet affirmed concerns about psilocybin ingestion in uncontrolled circumstances potentially leading to acute psychological distress, risky behavior, or enduring psychological symptoms. However, when psilocybin is given in laboratory studies to screened, prepared, and supported participants the incidence of risky behavior or enduring psychological distress is extremely low.
Biography
Roland R. Griffiths, Ph.D., is professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine. His principal research focus in both clinical and preclinical laboratories has been on the behavioral and subjective effects of mood-altering drugs. His research has been largely supported by grants from the National Institute on Health and he is author of over 300 journal articles and book chapters. He has been a consultant to the National Institutes of Health, and to numerous pharmaceutical companies in the development of new psychotropic drugs. He is also currently a member of the Expert Advisory Panel on Drug Dependence for the World Health Organization. He has an interest in meditation and is the lead investigator of the psilocybin research initiative at Johns Hopkins, which includes studies of psilocybin occasioned mystical experience in healthy volunteers and cancer patients, and a pilot study of psilocybin-facilitated smoking cessation.

Psychedelic therapy panel at the Interdisciplinary Conference on Psychedelics Research 2016. With Alicia Danforth, Rick Doblin,  Marcela Ot’Alora, Bill Richards, Friederike Meckel Fisher and Jeff Guss.

This talk will focus on the regulatory challenges involved in developing psychedelic-assisted psychotherapy through the FDA/EMA process. Issues to be discussed will be the initial reasons behind the strategy of working through the FDA/EMA process, the rationale for why MAPS is prioritizing MDMA as the psychedelic and PTSD as the clinical condition to move first into Phase 3 trials, standardizing the therapeutic method with treatment manual and adherence criteria, how we approached the double-blind issue, the importance of an outcome measure that is administered by Independent Raters and the procedure we’ll use to minimize bias, how we reached out to the Department of Defense and Department of Veterans Affairs National Center for PTSD, the issue of the FDA’s Risk Evaluation and Mitigation System (REMS) to regulate MDMA-assisted psychotherapy post-approval, and the FDA’s data exclusivity program and MAPS’ sustainability plan through our MAPS Public Benefit Corporation.

Existential distress in reaction to a life-threatening illness is often undertreated and mistreated in western medicine.  A randomized clinical trial of psilocybin assisted therapy for treatment of existential distress in cancer patients was recently completed at NYU School of Medicine with Stephen Ross, MD, Principal Investigator and Drs. Anthony Bossis, PhD and Dr. Guss as Co-Principal Investigators.   The results will be published as “Rapid and Sustained Symptom Reduction following Psilocybin Treatment for Anxiety and Depression in Patients with Life-Threatening Cancer:  A Randomized Controlled Trial” during 2016. During talk, Dr. Guss will describe the NYU study in detail, including its history, the structure and content of the therapy sessions and our method for training clinicians to work as study therapists.   After presenting outcome data from the study, a short film with participants from the study will be shown.
Biography
Jeffrey Guss, MD is a psychiatrist, psychoanalyst, and researcher with a specializations in psychoanalytic therapy and the treatment of substance used disorders. He is a Co-Principal Investigator, study therapist and the Director of Therapist Training for the NYU School of Medicine’s study on psilocybin-assisted psychotherapy in the treatment of existential distress related to cancer diagnosis and treatment, and is a co-author of “Rapid and Sustained Symptom Reduction Following Psilocybin Treatment for Anxiety and Depression in Patients with Life-Threatening Cancer: A Randomized Clinical Trial”. He is also a study therapist for NYU School of Medicine’s “Psilocybin Treatment of Alcohol Dependence” RCT study.
Dr Guss is particularly interested in the integration of psychedelic therapies with contemporary models of psychodynamic therapy and exploration of the practice models for future use of psychedelic medicines in clinical practice. He is an Instructor, Mentor and on the Council of Advisors for the California Institute of Integral Studies’ Center for Psychedelic Therapies and Research and on the Advisory Board for the Center for Optimal Living’s Psychedelic Education and Continuing Care Program. He has published on the topics of gender and sexuality in Studies in Gender and Sexuality and Psychoanalysis, Culture and Society. Dr. Guss maintains a private practice of psychiatry and psychotherapy in New York City.

This lecture provides a rough overview of four decades of research into psychedelics in Europe and the US.
Research “started again” in the mid-eighties, when European and American researchers penetrated through administrative barriers. Early MDMA psychotherapy research began in the end-1970s, modern German studies into mescaline and MDEA began in the late 1980s. Since 1985 the founding of the Swiss Physicans Society for Psycholytic therapy (SAEPT) and the European College for the Study of Consciousness (ECSC) by Leuner, Albert Hofmann and others triggered these developments. The founding of the Multidisciplinary Association for Psychedelic Studies (MAPS) in 1986 and the  Heffter Research Institute (HRI) in 1993 and later marked the stabilization of developments. A lot of research studies was initiated since the beginning 1990s, especially in respect to MDMA. MDE and psilocybin.
Since 2010 the scientific climate changed, partially because of ineffective antidepressants and malign side-effects of psychopharmacological medications. Another track came from the realization of the complexitiy of brain function. Substances which were formerly called “dirty drugs” for being not specific to one receptor (system) became interesting again because they may configurate a matrix of brain-functioning helpful for healing. Psychotherapy-promoting drugs like some psychedelics may become relevant therapeutic options in the future.
A retrospective view suggests a wave-like pattern of interest in psychedelics. Appropriate recognition of the limits of using these substances in everyday psychiatric/psychotherapeutic practice is discussed.
Biography
Torsten Passie (*1961) is currently Visiting Professor at Harvard Medical School (Boston, USA). He studied philosophy, sociology (M.A.) at Leibniz-University, Hannover and medicine at Hannover Medical School. His medical dissertation was on existential psychiatry. He worked at the Psychiatric University Clinic in Zürich (Switzerland) and with Professor Hanscarl Leuner (Göttingen), the leading European authority on hallucinogenic drugs. His extensive research at Hannover Medical School covers the psychophysiology of altered states of consciousness and their healing potential, including clinical research with hallucinogenic drugs (cannabis, ketamin, nitrous oxide, MDMA, psilocybin). He is an internationally known expert on altered states of consciousness and the pharmacology of hallucinogenic drugs. His publications appeared in Journal of Psychopharmacology, Neuropsychobiology, Addiction, CNS Neuroscience and Therapeutics, Journal of Nervous and Mental Disease and others.

Brain imaging and depression research with psychedelics
The talk will review brain imaging work on the action of psychedelics on the brain and describe the results of a clinical trial assessing psilocybin as a treatment for depression. It will also review the broader societal impact of psychedelic drug-use and discuss its implications.
Biography
Robin Carhart-Harris studies the brain effects of LSD, psilocybin (magic mushrooms), and MDMA. Most recently he has completed the first phase of a clinical trial looking at the potential of psilocybin to treat depression.